Supported Projects
-
2022 - 2024 A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
-
2021 - 2023 NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19
-
2020 - 2021 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
Other International Funding Programs
Eser F., Tabak Ö. F., Kumar S., Güner H. R., Conrad S., Tremblay A., et al.
-
2020 - 2021 CALAVI, A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
Other International Funding Programs
Eser F., Doğanay H. L., Batırel A., Olmuşçelik O., Güner H. R., Kart Yaşar K.
-
2020 - 2020 Hafif ve Orta Şiddetli COVID-19 Olgularında Hidroksiklorokin ve Favipiravirinin Güvenlilik ve Etkililiğini Değerlendiren Çok Merkezli, Paralel Gruplu, Randomize, Açık Etiketli, Faz III Çalışma
-
2013 - 2015 Kırım Kongo Kanamalı Ateşi hastalığında Rutin Laboratuar Tetkiklerinin Viral Yükle İlişkisi, Mortalite ile İlişkili Risk Faktörleri